Journal
CANCER CELL
Volume 40, Issue 6, Pages 569-574Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.04.006
Keywords
-
Categories
Funding
- National Institutes of Health [P30 CA008748, R01 CA236615-01, R01 CA235667]
- U.S. Department of Defense [BC132124, LC160212, CA170630, CA180889, CA200437]
- Comedy vs Cancer Award
- DallePezze Foundation
- Derfner Foundation
- Esophageal Cancer Education Fund
- Geoffrey Beene Foundation
- Memorial Sloan Kettering Technology Development Fund
- Miner Fund for Mesothelioma Research
- Commonwealth Foundation for Cancer Research
- Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center
- ATARA Biotherapeutics
- Batishwa Fellowship
Ask authors/readers for more resources
The success of CAR T cell therapy in solid tumors is limited by insufficient tumor infiltration and T cell dysfunction. However, regional delivery of CAR T cells in solid tumor patients is safe and feasible, promoting tumor infiltration, proliferation, and trafficking, leading to persisting systemic immunity.
The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
